A detailed history of Leelyn Smith, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Leelyn Smith, LLC holds 473 shares of VRTX stock, worth $213,308. This represents 0.04% of its overall portfolio holdings.

Number of Shares
473
Previous 478 1.05%
Holding current value
$213,308
Previous $224,000 2.23%
% of portfolio
0.04%
Previous 0.04%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$460.0 - $505.78 $2,300 - $2,528
-5 Reduced 1.05%
473 $219,000
Q2 2024

Aug 08, 2024

SELL
$392.81 - $485.53 $5,106 - $6,311
-13 Reduced 2.65%
478 $224,000
Q1 2024

May 13, 2024

BUY
$407.69 - $446.08 $200,175 - $219,025
491 New
491 $205,000
Q2 2023

Aug 10, 2023

SELL
$314.42 - $351.91 $54,080 - $60,528
-172 Reduced 16.78%
853 $300,000
Q1 2023

May 12, 2023

SELL
$283.23 - $323.1 $237,913 - $271,404
-840 Reduced 45.04%
1,025 $322,000
Q4 2022

Feb 10, 2023

BUY
$285.76 - $321.48 $299,762 - $337,232
1,049 Added 128.55%
1,865 $538,000
Q3 2022

Nov 14, 2022

SELL
$273.83 - $305.53 $500,013 - $557,897
-1,826 Reduced 69.11%
816 $236,000
Q2 2022

Aug 09, 2022

SELL
$234.96 - $292.55 $529,599 - $659,407
-2,254 Reduced 46.04%
2,642 $744,000
Q1 2022

May 11, 2022

BUY
$221.42 - $260.97 $32,327 - $38,101
146 Added 3.07%
4,896 $1.28 Million
Q4 2021

Feb 14, 2022

BUY
$177.01 - $223.45 $97,532 - $123,120
551 Added 13.12%
4,750 $1.04 Million
Q3 2021

Nov 12, 2021

BUY
$181.39 - $202.99 $12,515 - $14,006
69 Added 1.67%
4,199 $762,000
Q2 2021

Aug 31, 2021

SELL
$187.49 - $221.1 $110,056 - $129,785
-587 Reduced 12.44%
4,130 $833,000
Q1 2021

May 05, 2021

BUY
$207.02 - $241.31 $976,513 - $1.14 Million
4,717 New
4,717 $1.01 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Leelyn Smith, LLC Portfolio

Follow Leelyn Smith, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Leelyn Smith, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Leelyn Smith, LLC with notifications on news.